Hepatic microabscesses during CMV reactivation in a multiple sclerosis patient after alemtuzumab treatment.

[1]  W. Brownlee,et al.  Opportunistic infections after alemtuzumab: New cases of norcardial infection and cytomegalovirus syndrome , 2017, Multiple sclerosis.

[2]  L. Durelli,et al.  Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab , 2017, Multiple sclerosis.

[3]  H. Hartung,et al.  Alemtuzumab: A new therapy for active relapsing–remitting multiple sclerosis , 2015, Multiple sclerosis.

[4]  M. Minemura,et al.  Liver involvement in systemic infection. , 2014, World journal of hepatology.

[5]  M. Keating,et al.  Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab. , 2006, Clinical lymphoma & myeloma.

[6]  R. Kurzrock,et al.  Phase II study of alemtuzumab in chronic lymphoproliferative disorders , 2003, Cancer.

[7]  R. Mercier,et al.  Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J K Greenson,et al.  Mini‐microabscess syndrome in liver transplant recipients , 1997, Hepatology.

[9]  J. Hamilton,et al.  Cytomegalovirus infection following liver transplantation: review of the literature. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  E. Urbán,et al.  Cytomegalovirus infection in patients with haematological diseases and after autologous stem cell transplantation as consolidation: a single-centre study , 2016, Annals of Hematology.

[11]  N. Kaplowitz,et al.  Drug-Induced Liver Injury , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.